{"ticker": {"uuid": "79bd998f-0c56-4104-a5e0-7fb5bb1e2945", "symbol": "TSHA", "name": "Taysha Gene Therapies\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Does Rett Trial Data and Share Offering Reshape the Bull Case for Taysha Gene Therapies (TSHA)?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-16T14:56:30+00:00", "published_display": "16 Jul 2026 14:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOUFBRM2ZveGtvOFlVR3hRdkFxU0RpOTJfUWU1Z1NOT1lMZHFzNlY4eGllM2Nwc1JSQkM5NThSZ0Y0X1NScklYdnlBMy0tOGp3WVVzTkhNMnBVeENVV0JJZWxEWDVQZWxMQ0F3aUtOelRrSnRtY3dYUzV2b1EzdFAwLWVIdGpNd20zVVUwTTd5U1ltQzJoRmc?oc=5", "source_name": "Market source", "published_at": "2026-07-15T14:01:45+00:00", "published_display": "15 Jul 2026 14:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Taysha Gene Therapies Insider Sold Shares Worth $1,248,000, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/taysha-gene-therapies-insider-sold-075803316.html", "source_name": "MT Newswires", "published_at": "2026-07-13T07:58:03+00:00", "published_display": "13 Jul 2026 07:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run", "summary": "", "url": "https://finance.yahoo.com/m/a985e70b-d2e8-3772-bf25-26704ed81d07/taysha%27s-r%26d-chief-sold-%241.2.html", "source_name": "Motley Fool", "published_at": "2026-07-12T18:15:12+00:00", "published_display": "12 Jul 2026 18:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies president sells $1.25m in stock By Investing.com", "summary": "Taysha Gene Therapies' President and Head of Research & Development, Nagendran Sukumar, sold 200,000 shares of company stock for $1.25 million on July 10, 2026, as part of a pre-planned trading strategy. This sale occurred while TSHA shares have surged 149% over the past year, th", "url": "https://ng.investing.com/news/stock-market-news/taysha-gene-therapies-president-sells-125m-in-stock-93CH-2595727", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T22:40:38", "published_display": "11 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies president sells $1.25m in stock", "summary": "The President and Head of Research & Development at Taysha Gene Therapies, Nagendran Sukumar, sold 200,000 shares of company stock for $1.25 million on July 10, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan. The sale follows a significant 149% surge in TSH", "url": "https://www.investing.com/news/insider-trading-news/taysha-gene-therapies-president-sells-125m-in-stock-93CH-4787152", "source_name": "Investing.com", "published_at": "2026-07-11T10:40:28", "published_display": "11 Jul 2026 10:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha Gene Therapies Inc (TSHA)", "summary": "Sukumar Nagendran, President and Head of Research and Development at Taysha Gene Therapies Inc (TSHA), sold 200,000 shares of the company on July 10, 2026. This transaction increased his total sales over the past year to 1,343,276 shares, with no purchases. The stock is currently", "url": "https://www.gurufocus.com/news/8954309/insider-sell-sukumar-nagendran-sells-200000-shares-of-taysha-gene-therapies-inc-tsha?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-11T10:40:28", "published_display": "11 Jul 2026 10:40", "sentiment": "negative", "sentiment_pct": 27, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (TSHA) Could Be 49% Below Fair Value After Russell Index Drop", "summary": "Taysha Gene Therapies (TSHA) was recently removed from several Russell indexes, yet its share price has shown strong recent performance. According to a common valuation model, the stock is currently undervalued by 48.9% at $6.57 compared to a fair value of $12.85, driven by progr", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-could-be-49-below-fair-value-afte", "source_name": "Simply Wall Street", "published_at": "2026-07-10T23:10:52", "published_display": "10 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (NASDAQ: TSHA) R&D chief sells 200,000 shares under plan", "summary": "Nagendran Sukumar, President and Head of R&D of Taysha Gene Therapies (NASDAQ: TSHA), sold 200,000 shares of common stock on July 10, 2026, at a weighted average price of $6.24 per share. This sale was conducted under a pre-established Rule 10b5-1 trading plan adopted in June 202", "url": "https://www.stocktitan.net/sec-filings/TSHA/form-4-taysha-gene-therapies-inc-insider-trading-activity-4a7dd24650ae.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:10:29", "published_display": "10 Jul 2026 23:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Taysha Gene Therapies For: 10 July By Investing.com", "summary": "This article from Investing.com reports that a Form 144 was filed for Taysha Gene Therapies on July 10th. Form 144 is a notice of the intent to sell restricted securities. The article provides no further details about the filing but includes a stock market quote for TSHA, which w", "url": "https://ng.investing.com/news/stock-market-news/form-144-taysha-gene-therapies-for-10-july-93CH-2595536", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T21:34:00", "published_display": "10 Jul 2026 21:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (TSHA) investor files to sell 200,000 shares via Jefferies", "summary": "A Taysha Gene Therapies (TSHA) shareholder, Sukumar Nagendran, has filed to sell up to 200,000 shares of common stock through Jefferies LLC on or after July 10, 2026, with an estimated market value of $1,298,000. Nagendran previously sold 200,000 shares for $831,300 within the la", "url": "https://www.stocktitan.net/sec-filings/TSHA/144-taysha-gene-therapies-inc-sec-filing-a10d79023e01.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:10:29", "published_display": "10 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha G", "summary": "Sukumar Nagendran, President and Head of Research and Development at Taysha Gene Therapies Inc (TSHA), sold 200,000 shares of the company on July 10, 2026. This transaction adds to a pattern of 11 insider sells and no buys over the past year. With the stock trading at $6.24 and a", "url": "https://www.gurufocus.com/news/8954309/insider-sell-sukumar-nagendran-sells-200000-shares-of-taysha-gene-therapies-inc-tsha", "source_name": "GuruFocus", "published_at": "2026-07-10T19:01:00", "published_display": "10 Jul 2026 19:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Russell Index Removals and New Rett Data Change Taysha Gene Therapies' (TSHA) Narrative?", "summary": "Taysha Gene Therapies (TSHA) was recently removed from several Russell indices, coinciding with the release of new long-term clinical data for its TSHA-102 Rett syndrome gene therapy. This article examines how these events impact the company's investment narrative, focusing on ne", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/will-russell-index-removals-and-new-rett-data-change-taysha/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-08T09:40:56", "published_display": "08 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Taysha Gene Therapies, Inc. (TSHA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFB0NThaekJIbC02QkxCTmFrNzc1TzRVeV9mR0wwQTBmWDJMbUJlWHVQNnVoRWprbUczdXlZN01nR3B2YlM4LVc1dkQ4X2FBbFhfT0paMUY5dkE2SVg5SjFQRVQ5cmtJWGJtaTg2Rkt3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-04T00:55:07+00:00", "published_display": "04 Jul 2026 00:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates Taysha Gene Therapies stock rating on therapy progress", "summary": "Citizens reiterated a Market Outperform rating and an $11.00 price target for Taysha Gene Therapies (NASDAQ:TSHA) based on progress in its TSHA-102 program for Rett Syndrome. The firm remains optimistic ahead of pivotal data and regulatory feedback expected in early 2027, noting ", "url": "https://m.uk.investing.com/news/stock-market-news/citizens-reiterates-taysha-gene-therapies-stock-rating-on-therapy-progress-93CH-4754414?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-02T14:11:44", "published_display": "02 Jul 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha\u2019s TSHA-102 Rett Data Links Clinical Promise To Future Revenue", "summary": "Taysha Gene Therapies (TSHA) reported positive early results from its REVEAL Phase 1/2 trial for TSHA-102 in Rett syndrome, showing a 100% responder rate and durable functional improvements with a favorable safety profile. The company is accelerating commercial manufacturing prep", "url": "https://www.sahmcapital.com/news/content/tayshas-tsha-102-rett-data-links-clinical-promise-to-future-revenue-2026-06-13", "source_name": "Sahm", "published_at": "2026-07-01T20:40:25", "published_display": "01 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. \u2013 NASDAQ:TSHA", "summary": "This page from TradingView provides financial information for Taysha Gene Therapies, Inc. (NASDAQ: TSHA), specifically focusing on its enterprise value to EBITDA forward metric. The content indicates market data and various navigational links related to financial tools and commun", "url": "https://www.tradingview.com/symbols/NASDAQ-TSHA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T08:41:32", "published_display": "01 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. \u2013 BOATS:TSHA", "summary": "This page provides financial data, specifically the Enterprise Value to EBITDA forward, for Taysha Gene Therapies, Inc. (TSHA). It highlights that the information is presented without active trading data, indicating a market closed or no-trade status at the time of viewing. The c", "url": "https://www.tradingview.com/symbols/BOATS-TSHA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T06:30:17", "published_display": "01 Jul 2026 06:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Taysha Gene Therapies, Inc. \u2013 NASDAQ:TSHA", "summary": "This article provides a brief mention of the \"Price to sales forward\" metric for Taysha Gene Therapies, Inc. (NASDAQ: TSHA). It appears to be a financial data point from TradingView, indicating a period value and changes but without specific numerical details in the snippet provi", "url": "https://www.tradingview.com/symbols/NASDAQ-TSHA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T19:09:13", "published_display": "30 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Taysha Gene Therapies, Inc. \u2013 BOATS:TSHA", "summary": "The article focuses on the \"Price to sales forward\" metric for Taysha Gene Therapies, Inc. (TSHA), which is listed on the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data point from TradingView, indicating a specific valuation ratio for the company.", "url": "https://www.tradingview.com/symbols/BOATS-TSHA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T09:40:21", "published_display": "30 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Taysha Gene Therapies, Inc. \u2013 NASDAQ:TSHA", "summary": "This article provides access to the \"Price to book forward\" financial metric for Taysha Gene Therapies, Inc. (NASDAQ: TSHA) on the TradingView platform. It details how users can find this information within the financial section of TSHA's profile, emphasizing data provided by ICE", "url": "https://www.tradingview.com/symbols/NASDAQ-TSHA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:40:21", "published_display": "30 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Taysha Gene Therapies, Inc. \u2013 BOATS:TSHA", "summary": "This article provides financial information for Taysha Gene Therapies, Inc. (TSHA) on the TradingView platform. It specifically looks at the company's forward price-to-earnings ratio. The content also lists various features and resources available on TradingView for financial ana", "url": "https://www.tradingview.com/symbols/BOATS-TSHA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T01:11:36", "published_display": "30 Jun 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rett Data and $200 Million Raise Might Change The Case For Investing In Taysha (TSHA)", "summary": "Taysha Gene Therapies recently completed a $200 million equity raise and released encouraging longer-term data from its REVEAL trial for TSHA-102 in Rett syndrome patients, showing durable functional gains and a good safety profile. Despite being delisted from some Russell indice", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/rett-data-and-200-million-raise-might-change-the-case-for-in", "source_name": "Simply Wall Street", "published_at": "2026-06-29T12:11:46", "published_display": "29 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 3000E Growth Benchmark", "summary": "Taysha Gene Therapies, Inc. (NasdaqGS:TSHA) has been removed from the Russell 3000E Growth Benchmark. The company is a clinical-stage biotechnology firm focusing on AAV-based gene therapies for severe central nervous system monogenic diseases, with its lead program TSHA-102 targe", "url": "https://www.marketscreener.com/news/taysha-gene-therapies-inc-nasdaqgs-tsha-dropped-from-russell-3000e-growth-benchmark-ce7f5fdedf89f120", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T04:31:00", "published_display": "29 Jun 2026 04:31", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies launches $200 million stock offering", "summary": "Taysha Gene Therapies, a clinical-stage biotechnology company, has initiated an underwritten public offering of common stock and pre-funded warrants valued at $200 million. This move follows a significant 189% gain in its shares over the past year, although the stock appears over", "url": "https://www.investing.com/news/company-news/taysha-gene-therapies-launches-200-million-stock-offering-93CH-4758886", "source_name": "Investing.com", "published_at": "2026-06-25T20:41:07", "published_display": "25 Jun 2026 20:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting", "summary": "Taysha Gene Therapies announced multiple presentations at the 2026 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting, showcasing its TSHA-102 gene therapy program. The presentations will cover safety and efficacy data from the REVEAL Part A Phase 1/2 ", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317925/0/en/taysha-gene-therapies-announces-multiple-presentations-highlighting-its-tsha-102-clinical-program-at-the-2026-irsf-rett-syndrome-scientific-meeting.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T20:10:46", "published_display": "25 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha lines up TSHA-102 data on Rett syndrome at June 29 meeting", "summary": "Taysha Gene Therapies (Nasdaq: TSHA) will present multiple updates on its TSHA-102 program for Rett syndrome at the 2026 IRSF Rett Syndrome Scientific Meeting from June 29 to July 1, 2026. The presentations will include longer-term REVEAL Part A clinical data, natural history ins", "url": "https://www.stocktitan.net/news/TSHA/taysha-gene-therapies-announces-multiple-presentations-highlighting-mumajeqwcu1g.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:10:46", "published_display": "25 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Prices Equity Offering for ~$187.4 Million Net, Grants 5 Million Share Option", "summary": "Taysha Gene Therapies announced an equity offering to sell over 33 million shares and pre-funded warrants at $6.00 per share, expecting to net approximately $187.4 million. The company has also granted underwriters an option to purchase up to 5 million additional shares, which co", "url": "https://www.tradingview.com/news/tradingview:5678614f78299:0-taysha-gene-therapies-prices-equity-offering-for-187-4-million-net-grants-5-million-share-option/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:46", "published_display": "25 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (NASDAQ: TSHA) prices $200M equity raise with warrants", "summary": "Taysha Gene Therapies (NASDAQ: TSHA) has priced an underwritten public offering to raise approximately $200 million in gross proceeds through the sale of common stock and pre-funded warrants. The company will sell 32,500,001 common shares at $6.00 each and pre-funded warrants for", "url": "https://www.stocktitan.net/sec-filings/TSHA/8-k-taysha-gene-therapies-inc-reports-material-event-4ee76b43942b.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:10:46", "published_display": "25 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Down Over 11%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk", "summary": "Taysha Gene Therapies (TSHA) stock is down over 11% today, experiencing its largest percentage decrease since May 2025. This downturn follows five consecutive days of gains, during which the stock rose by 4.2%. The current trading volume is significantly lower than its 65-day ave", "url": "https://www.moomoo.com/news/post/72053872/taysha-gene-therapies-down-over-11-on-pace-for-largest?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-25T19:10:46", "published_display": "25 Jun 2026 19:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Prices $200 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/taysha-gene-therapies-prices-200-084319338.html", "source_name": "MT Newswires", "published_at": "2026-06-25T08:43:19+00:00", "published_display": "25 Jun 2026 08:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Prices $200 Million Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNaU5fbjBSREU5UnZ1VFFjX1ZnZUhfX0d5VkJZcUZuRFo5eXpYNExmTEtkXzB4ZEowTlU1WGNRVE1oSUVOeUNWRHV5bjkwSWpYdFBBZ29MaTN1ei1nXzdvbjgzczMtTnM5aGFqYUVRVnE5czhkZlp6VXRNQVh6a1BEWkVtRU9hdEFXLWN2X1dkNUVXVV9heGNuUXhwYU9Pb3M2ei1saFpudVhSQkdvWlRBeGVJLXdqbU0xeDJrSWZSZFJabXhPUVdNenVCXzM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies stock tumbles on public offering pricing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNS1FEXzZQeVBleVJjQzF4MTVSNGJwVDlRdmlXbGxaLWdWSFhRLW51YU1MenI1Z1pLM19iSk9tLUJqN1VmTi1RTGVnVXd6YXVQSVpDYmFhYzNZWU42Y01QSjlISFFlcVdTVTRTdFFWakhsZDV2RDMya0w1WERKMlhHeWRLc1RXMVZnQUg5djI1d1VPZ1FZbDA3Nmt0OTZtaVc0Z1J1bjRUa2l2WFJsRGJmSlRTbTR1SXVtSzJOOGxhemhEQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Inc Files For Mixed Shelf Offering Of Up To $200 Million - SEC Filing", "summary": "Taysha Gene Therapies Inc has filed for a mixed shelf offering of up to $200 million, as disclosed in an SEC filing. This information was reported as part of standard financial news.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42W0GB:0-taysha-gene-therapies-inc-files-for-mixed-shelf-offering-of-up-to-200-million-sec-filing/", "source_name": "TradingView", "published_at": "2026-06-25T03:41:06", "published_display": "25 Jun 2026 03:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies prices $200M stock offering at $6 per share", "summary": "Taysha Gene Therapies has priced an underwritten public offering of 32,500,001 shares of common stock at $6.00 per share, aiming to raise approximately $200 million. The company also offered pre-funded warrants and granted underwriters a 30-day option for additional shares. This ", "url": "https://www.investing.com/news/company-news/taysha-gene-therapies-prices-200m-stock-offering-at-6-per-share-93CH-4759639", "source_name": "Investing.com", "published_at": "2026-06-25T03:03:06", "published_display": "25 Jun 2026 03:03", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Launches $200 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/taysha-gene-therapies-launches-200-202528925.html", "source_name": "MT Newswires", "published_at": "2026-06-24T20:25:28+00:00", "published_display": "24 Jun 2026 20:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxQZXlnMjRETmtoMjNEZVJ2T1hpR0JVYmxFcmpvWnllMjZDSDRKRGNFNTNKNjlDUGlMVDEzTkN3SGhzenRFdG1zMzh0Q3pjd3NwUW5IOE9GZGZaOF83cURtQlo3bzVoRHJwUTgxdUZTY3VMbUFDY09vWXlOek5UYkUtX2pwTHQ2WU5OVVB3X3hjYWZ3eEE1R19jU3EzOTJTQUdlVm41TE9pVndWQ2UzN2dndDNrRm80U1F4X1l2RUJDMGZ6c18tRy11UGVWSDI1ZzRvNGRNQ3pRMmx5UnFocnFNY2tTdlpvWmNVSXQ2RkJWNmptblRaWHlrbkJIa3B2a2c?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxPbldxZDlTZFdQQUFGdXJUaU9YWmlYbmpBeGdyemtmV2tERVJjTkxteEx0bUF0OE1RN2tSM0pFZldvbTJtWWlEZTZfYkFyb2h1Y19na3N6Rnhvc2lNZk9RY3pJLUpheVVUSHd1QmMyWkFhbzhBVUpWcE1hSTlsbmlGS3hxOXgwMTdWNWcwLVlScDBzVW5OYWMwMFlPQ3VJOEtCWkRRM3RveUtXU0U0QXFZR1NSRkw2RlcxWHJYbXhQbFJOQVJJU1lvZ0JWWnNtUHpoUklQbjdTekJTMUhUOWRaVHFYcFRUUlE0VUNmV2Z5ZmtFMDZIOFV2MDBZNkY?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (TSHA) files $200M common stock and pre-funded warrants offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQN0pCRlRZcWtnSGJTOGs5SFBkRDBPandoMU1SNjVJWndwbUVyOG5OMGtWRlhUdllOSEptM0lFd29iZWxuZTlJNmNTSE93cDBTSjFPbmlzM2daQ0NNeFYxOU84VEtvY29zVGo3TWZvVG1GYVc4WEJIVWtYSXBIVUduQUdmOFl5Tm5NaDJGcHBuTjNraUVGWlZwazZBMUNsYjh3Qml4TjVZc29MUVNYYzlwaDRsYVQwZGlSRGF6dTZVQkZxVWJpWVFMcVVDdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha prices $200M offering as closing nears June 26", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRUxGeFVpcFY2aEV0UmkzX01IaFNIYkRRSGRCaXlCUGJfVUgxbjd2bHQ2b3Y2andQYUNhcUJHWXZ4VVh2X2Y3SEZIUE1tUi1FTFNZdW92aG85elkzVlp4MHQ2UzhtT3BnQUZ2a1ZxSmZnVFlOTE50eURmYWtrQ1FaWG5xc05mZzQ5d0E3S2hFQU9vV0llVjBLYk1BX3F5Vm9VN2paSWdndUx3blpfRVJ5Tl9uaThwWUlBQVRaS3ZjZG8?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)", "summary": "", "url": "https://finance.yahoo.com/m/3db0036d-6fb1-3e40-ab7a-37807122dabc/taysha-advances-rett-syndrome.html", "source_name": "InvestorsHub", "published_at": "2026-06-22T12:56:24+00:00", "published_display": "22 Jun 2026 12:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies stock price target raised to $10 by BofA on trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQWnBpdzF4RkZDa3kwNXMzZE1QUXdxNVFvSDdkaFY1SDhma0pZN2RubEtZUFhwSm1KcFNCR2NtaE03OVdCazJFTTQ1dWhnUXh0Q2pZMEJDVFJNbUNrOWt1V1NxamJnZHNtcXJBWVd2SW9KUE82YVJnM2ZObnVlZDZoTWtkb2U1SW9QQ1lHeGVEOEJ2WElad1Bpb0NLdHhZcEtqQjRLZFVpczVfQ0swQkJWeDJMT3FCRnJzT0xBNUJlbUZVeG9Yd1h4TjRmM3lMT2JQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year Recovery", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNLTRmeFRWaDB1ckdoZFQ0bVh4SlMzMUFKX1BvMWFmOG0zWFI2T1lXazZaWGY3LWlMVy1KeDlpRXVrMXJQZHdMSWRBb1lsVGJoMEtaMjdMM3dhZkdEeklkenJoVG9LNnRncVhBY3FELTJNZ2k2RWQ2TERnTWhObzBWTGhhbmFvek1zd0hwN3ZnVTVac0tVQWNoRWt5MVYwQ0IwenJB?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQQnBDVHBPMm1CYmNsVGF6WFluSlkzTzJTdkVlZWMyZVJ5REVvYnlRbEl2VkNINVRoWDdDMGpCejV2VzVUMlJvcnlkaGRyZW9QODdSd2JvQTA4R3AwSllETHpKUWxPclBzWFJoa2NZbFZ3SVI2V2lmMU1kWWZXOTJfNjlaTk5pZ1M5dkVWUGU2NWFMbFBydUw2OVdOWQ?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies: Shortened Timeline Increases The Potential (NASDAQ:TSHA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOUVV3anZ6WnBtQU1rSHo5QWJLaUdCM2JpR1NKSDVyVFR1NXNVSG9GU1FGTDNqMk5yU0Z5NHpFUUpDTE9xWjBrRmZ1cDFsVmR1U0hsNDdKcEo1MGx0cFM0eWpZcGlwZmY1MHdaRzREZ1ZHcnRSbGozdGhkUm5FdUxLa1VfcVRfMi0xUXhJNm9jeEJhaXppdVQ2MWN4bDVYM0JscFRNVTZveHpJZ0RITFQ3MQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQcGJEclQ2QW5tOC1OM2lvZHo5NlNKSjV2X0NIRS1qRjBzZG41RGJyNTFNUWRDSmp4RHFyMFRxTm5XNEZPbk1iazYxQW9LM1lkd2ZCZkpBMjV2TjdSWXBuTTh3eTVpa2JHV3FFblVuTEdVVmFmeTdHQmlkT2hfRTI4WkNHbGdhZVQwZkVrdU9oZkFYbWxScDR5YmtLRTBjUmdzMk41LWpn?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOSjBBWGdEUEU1Y3hyR3dKSGpwSG02OGphODFUVS1YR24zQ3I3UmJHeTZValZsNXJoRlp0SW82bHZFaDdYY21ZaWRBd0JiZE9jRmc0UUt5SHVhOVlySW1XOHlOcnljN0tXVUNsWTh1T1RidzJlSGhlUDJpcWNzenNadzBtRlI4b1RCZnVZWGVEeFQyY0JBcjROUmYwMGlEU00xUFc0?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A 6-month trial readout could shape Taysha's gene therapy filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOUjg5S0htMGFFTDJEck1ETFMwOHZ0VVp4RHp1bm9oeHhDVWwtdTZnOHRvQ2VHTmgzdFZPMzN4TVM2Q0txYXhydkVNRkVhQS1ZNzFFdm41NGI0SzlzVXRTZW9KSFZ1c0JYeEN4clk1eEtsa1h6alA5NmNpVEJSZ0dOVGxlb1dXUERNeklueHBCa25lUlhtV05MZHNRU3Btb3FyYkRtUFBWMU5GeGZHbl8xcWJQTU1YQmI2b1ZmbERn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxObUpDY2NpUkdxcjlPeFJtTHFoaXRuZ0hDdXRtbl80d21CRWZrdjkwZGxBUWpnWTI5dndBa2pVR1B2b3N3UUtyampUa2piRW4zZ1F2S3lKaUREUUFXZlVJeUswRHIzcUdEM1FuMXZDOVVmTy05UkFMTzFtd296ZGx6dkRCbkE1Z2VwN1dKby1YVnBhYXRBNnBQMFZ2X1htaFBXTC01bFdzbWxvZDdOaUp3VmNTMFdET3NaQnlQT0VidlhTcnpzbkU1UFRVWERkUEdTVlJLVEhoVm1GbU92MnNKQnVNcHFvS1ZVaV9sVDY2c3F1a2Z2YUJZcVZKT3g?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxONEdFV3UzY2wyaFhHVHB4TWxlZDZjbXM2VkkwWkVyckZzYUJQRzAtOUNINjZtUGcwQUJ6cTVzZnRicEwwZllsSU1uWTRfaUNtRWFPRGFhUDBHOVJrTG1Dc2VmUFAxU1lVWWR5c1BqR19vNFFMdlJZMWlzS1FZZnprc09RWjdsczRVc3ZaS0NJeHg4NXBGdU9jOWdYZw?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Reports Preclinical Data Supporting TSHA-102 Gene Therapy for Rett Syndrome at ASGCT Annual Meeting | TSHA Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNRU13QXU5RFkyTHhfdkZMUGJoaVpYam9BMkZpYkZONHNXNnZFbmdKbGNJRk1jR0R0MUFTVjZXQnZiNXhONU44S1M0bU00c1hiVmVlZUZYd3pwT09GbjNTTEd4RUxfRFY1S1ZzY0E4LWpDRlBVUjlVaEdrZ3p3bWFDM2xkTWtEVlNHY0NKNFMwX3BkZ21sb19rNHdVcmtQYzVLSlhmbEFPNEpJZTVzcVM0dXl2WmNIWFEwM19iNkpRMVk2Z19IajN5dE5EX19GUkc0djgxRlVjdGFwWEEyWGhPQmxpVXJTQ05mMVE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQaG9nZGZUbjlZUnJyLWVOVTZWRi1WbTJQUFYzSlJWdEpfRmpLclNYZndKbFRtQzJ2YW9rMTBlcG95NFRGMkNqa0pQSjBOWEUxbE5HdlFoYWMyZ203Rm9Uc1BVMHFrRjdsYWlORjE5RWZMWlN3Z1Z4Z3lmQ3BuMGh2NGhjTmpOMjFuQ3FvSHQ0cEJ5WnNoSGpwSXFsNjI2Yi1zd2JJ?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Does Rett Trial Data and Share Offering Reshape the Bull Case for Taysha Gene Therapies (TSHA)?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-16T14:56:30+00:00", "published_display": "16 Jul 2026 14:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOUFBRM2ZveGtvOFlVR3hRdkFxU0RpOTJfUWU1Z1NOT1lMZHFzNlY4eGllM2Nwc1JSQkM5NThSZ0Y0X1NScklYdnlBMy0tOGp3WVVzTkhNMnBVeENVV0JJZWxEWDVQZWxMQ0F3aUtOelRrSnRtY3dYUzV2b1EzdFAwLWVIdGpNd20zVVUwTTd5U1ltQzJoRmc?oc=5", "source_name": "Market source", "published_at": "2026-07-15T14:01:45+00:00", "published_display": "15 Jul 2026 14:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Insider Sold Shares Worth $1,248,000, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/taysha-gene-therapies-insider-sold-075803316.html", "source_name": "MT Newswires", "published_at": "2026-07-13T07:58:03+00:00", "published_display": "13 Jul 2026 07:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run", "summary": "", "url": "https://finance.yahoo.com/m/a985e70b-d2e8-3772-bf25-26704ed81d07/taysha%27s-r%26d-chief-sold-%241.2.html", "source_name": "Motley Fool", "published_at": "2026-07-12T18:15:12+00:00", "published_display": "12 Jul 2026 18:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies president sells $1.25m in stock By Investing.com", "summary": "Taysha Gene Therapies' President and Head of Research & Development, Nagendran Sukumar, sold 200,000 shares of company stock for $1.25 million on July 10, 2026, as part of a pre-planned trading strategy. This sale occurred while TSHA shares have surged 149% over the past year, th", "url": "https://ng.investing.com/news/stock-market-news/taysha-gene-therapies-president-sells-125m-in-stock-93CH-2595727", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T22:40:38", "published_display": "11 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies president sells $1.25m in stock", "summary": "The President and Head of Research & Development at Taysha Gene Therapies, Nagendran Sukumar, sold 200,000 shares of company stock for $1.25 million on July 10, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan. The sale follows a significant 149% surge in TSH", "url": "https://www.investing.com/news/insider-trading-news/taysha-gene-therapies-president-sells-125m-in-stock-93CH-4787152", "source_name": "Investing.com", "published_at": "2026-07-11T10:40:28", "published_display": "11 Jul 2026 10:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha Gene Therapies Inc (TSHA)", "summary": "Sukumar Nagendran, President and Head of Research and Development at Taysha Gene Therapies Inc (TSHA), sold 200,000 shares of the company on July 10, 2026. This transaction increased his total sales over the past year to 1,343,276 shares, with no purchases. The stock is currently", "url": "https://www.gurufocus.com/news/8954309/insider-sell-sukumar-nagendran-sells-200000-shares-of-taysha-gene-therapies-inc-tsha?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-11T10:40:28", "published_display": "11 Jul 2026 10:40", "sentiment": "negative", "sentiment_pct": 27, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (TSHA) Could Be 49% Below Fair Value After Russell Index Drop", "summary": "Taysha Gene Therapies (TSHA) was recently removed from several Russell indexes, yet its share price has shown strong recent performance. According to a common valuation model, the stock is currently undervalued by 48.9% at $6.57 compared to a fair value of $12.85, driven by progr", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-could-be-49-below-fair-value-afte", "source_name": "Simply Wall Street", "published_at": "2026-07-10T23:10:52", "published_display": "10 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (NASDAQ: TSHA) R&D chief sells 200,000 shares under plan", "summary": "Nagendran Sukumar, President and Head of R&D of Taysha Gene Therapies (NASDAQ: TSHA), sold 200,000 shares of common stock on July 10, 2026, at a weighted average price of $6.24 per share. This sale was conducted under a pre-established Rule 10b5-1 trading plan adopted in June 202", "url": "https://www.stocktitan.net/sec-filings/TSHA/form-4-taysha-gene-therapies-inc-insider-trading-activity-4a7dd24650ae.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:10:29", "published_display": "10 Jul 2026 23:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Taysha Gene Therapies For: 10 July By Investing.com", "summary": "This article from Investing.com reports that a Form 144 was filed for Taysha Gene Therapies on July 10th. Form 144 is a notice of the intent to sell restricted securities. The article provides no further details about the filing but includes a stock market quote for TSHA, which w", "url": "https://ng.investing.com/news/stock-market-news/form-144-taysha-gene-therapies-for-10-july-93CH-2595536", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T21:34:00", "published_display": "10 Jul 2026 21:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (TSHA) investor files to sell 200,000 shares via Jefferies", "summary": "A Taysha Gene Therapies (TSHA) shareholder, Sukumar Nagendran, has filed to sell up to 200,000 shares of common stock through Jefferies LLC on or after July 10, 2026, with an estimated market value of $1,298,000. Nagendran previously sold 200,000 shares for $831,300 within the la", "url": "https://www.stocktitan.net/sec-filings/TSHA/144-taysha-gene-therapies-inc-sec-filing-a10d79023e01.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:10:29", "published_display": "10 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha G", "summary": "Sukumar Nagendran, President and Head of Research and Development at Taysha Gene Therapies Inc (TSHA), sold 200,000 shares of the company on July 10, 2026. This transaction adds to a pattern of 11 insider sells and no buys over the past year. With the stock trading at $6.24 and a", "url": "https://www.gurufocus.com/news/8954309/insider-sell-sukumar-nagendran-sells-200000-shares-of-taysha-gene-therapies-inc-tsha", "source_name": "GuruFocus", "published_at": "2026-07-10T19:01:00", "published_display": "10 Jul 2026 19:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Russell Index Removals and New Rett Data Change Taysha Gene Therapies' (TSHA) Narrative?", "summary": "Taysha Gene Therapies (TSHA) was recently removed from several Russell indices, coinciding with the release of new long-term clinical data for its TSHA-102 Rett syndrome gene therapy. This article examines how these events impact the company's investment narrative, focusing on ne", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/will-russell-index-removals-and-new-rett-data-change-taysha/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-08T09:40:56", "published_display": "08 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Taysha Gene Therapies, Inc. (TSHA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFB0NThaekJIbC02QkxCTmFrNzc1TzRVeV9mR0wwQTBmWDJMbUJlWHVQNnVoRWprbUczdXlZN01nR3B2YlM4LVc1dkQ4X2FBbFhfT0paMUY5dkE2SVg5SjFQRVQ5cmtJWGJtaTg2Rkt3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-04T00:55:07+00:00", "published_display": "04 Jul 2026 00:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates Taysha Gene Therapies stock rating on therapy progress", "summary": "Citizens reiterated a Market Outperform rating and an $11.00 price target for Taysha Gene Therapies (NASDAQ:TSHA) based on progress in its TSHA-102 program for Rett Syndrome. The firm remains optimistic ahead of pivotal data and regulatory feedback expected in early 2027, noting ", "url": "https://m.uk.investing.com/news/stock-market-news/citizens-reiterates-taysha-gene-therapies-stock-rating-on-therapy-progress-93CH-4754414?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-02T14:11:44", "published_display": "02 Jul 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha\u2019s TSHA-102 Rett Data Links Clinical Promise To Future Revenue", "summary": "Taysha Gene Therapies (TSHA) reported positive early results from its REVEAL Phase 1/2 trial for TSHA-102 in Rett syndrome, showing a 100% responder rate and durable functional improvements with a favorable safety profile. The company is accelerating commercial manufacturing prep", "url": "https://www.sahmcapital.com/news/content/tayshas-tsha-102-rett-data-links-clinical-promise-to-future-revenue-2026-06-13", "source_name": "Sahm", "published_at": "2026-07-01T20:40:25", "published_display": "01 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. \u2013 NASDAQ:TSHA", "summary": "This page from TradingView provides financial information for Taysha Gene Therapies, Inc. (NASDAQ: TSHA), specifically focusing on its enterprise value to EBITDA forward metric. The content indicates market data and various navigational links related to financial tools and commun", "url": "https://www.tradingview.com/symbols/NASDAQ-TSHA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T08:41:32", "published_display": "01 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. \u2013 BOATS:TSHA", "summary": "This page provides financial data, specifically the Enterprise Value to EBITDA forward, for Taysha Gene Therapies, Inc. (TSHA). It highlights that the information is presented without active trading data, indicating a market closed or no-trade status at the time of viewing. The c", "url": "https://www.tradingview.com/symbols/BOATS-TSHA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T06:30:17", "published_display": "01 Jul 2026 06:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Taysha Gene Therapies, Inc. \u2013 NASDAQ:TSHA", "summary": "This article provides a brief mention of the \"Price to sales forward\" metric for Taysha Gene Therapies, Inc. (NASDAQ: TSHA). It appears to be a financial data point from TradingView, indicating a period value and changes but without specific numerical details in the snippet provi", "url": "https://www.tradingview.com/symbols/NASDAQ-TSHA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T19:09:13", "published_display": "30 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Taysha Gene Therapies, Inc. \u2013 BOATS:TSHA", "summary": "The article focuses on the \"Price to sales forward\" metric for Taysha Gene Therapies, Inc. (TSHA), which is listed on the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data point from TradingView, indicating a specific valuation ratio for the company.", "url": "https://www.tradingview.com/symbols/BOATS-TSHA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T09:40:21", "published_display": "30 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Taysha Gene Therapies, Inc. \u2013 NASDAQ:TSHA", "summary": "This article provides access to the \"Price to book forward\" financial metric for Taysha Gene Therapies, Inc. (NASDAQ: TSHA) on the TradingView platform. It details how users can find this information within the financial section of TSHA's profile, emphasizing data provided by ICE", "url": "https://www.tradingview.com/symbols/NASDAQ-TSHA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:40:21", "published_display": "30 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Taysha Gene Therapies, Inc. \u2013 BOATS:TSHA", "summary": "This article provides financial information for Taysha Gene Therapies, Inc. (TSHA) on the TradingView platform. It specifically looks at the company's forward price-to-earnings ratio. The content also lists various features and resources available on TradingView for financial ana", "url": "https://www.tradingview.com/symbols/BOATS-TSHA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T01:11:36", "published_display": "30 Jun 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rett Data and $200 Million Raise Might Change The Case For Investing In Taysha (TSHA)", "summary": "Taysha Gene Therapies recently completed a $200 million equity raise and released encouraging longer-term data from its REVEAL trial for TSHA-102 in Rett syndrome patients, showing durable functional gains and a good safety profile. Despite being delisted from some Russell indice", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/rett-data-and-200-million-raise-might-change-the-case-for-in", "source_name": "Simply Wall Street", "published_at": "2026-06-29T12:11:46", "published_display": "29 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 3000E Growth Benchmark", "summary": "Taysha Gene Therapies, Inc. (NasdaqGS:TSHA) has been removed from the Russell 3000E Growth Benchmark. The company is a clinical-stage biotechnology firm focusing on AAV-based gene therapies for severe central nervous system monogenic diseases, with its lead program TSHA-102 targe", "url": "https://www.marketscreener.com/news/taysha-gene-therapies-inc-nasdaqgs-tsha-dropped-from-russell-3000e-growth-benchmark-ce7f5fdedf89f120", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T04:31:00", "published_display": "29 Jun 2026 04:31", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies launches $200 million stock offering", "summary": "Taysha Gene Therapies, a clinical-stage biotechnology company, has initiated an underwritten public offering of common stock and pre-funded warrants valued at $200 million. This move follows a significant 189% gain in its shares over the past year, although the stock appears over", "url": "https://www.investing.com/news/company-news/taysha-gene-therapies-launches-200-million-stock-offering-93CH-4758886", "source_name": "Investing.com", "published_at": "2026-06-25T20:41:07", "published_display": "25 Jun 2026 20:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting", "summary": "Taysha Gene Therapies announced multiple presentations at the 2026 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting, showcasing its TSHA-102 gene therapy program. The presentations will cover safety and efficacy data from the REVEAL Part A Phase 1/2 ", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317925/0/en/taysha-gene-therapies-announces-multiple-presentations-highlighting-its-tsha-102-clinical-program-at-the-2026-irsf-rett-syndrome-scientific-meeting.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T20:10:46", "published_display": "25 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha lines up TSHA-102 data on Rett syndrome at June 29 meeting", "summary": "Taysha Gene Therapies (Nasdaq: TSHA) will present multiple updates on its TSHA-102 program for Rett syndrome at the 2026 IRSF Rett Syndrome Scientific Meeting from June 29 to July 1, 2026. The presentations will include longer-term REVEAL Part A clinical data, natural history ins", "url": "https://www.stocktitan.net/news/TSHA/taysha-gene-therapies-announces-multiple-presentations-highlighting-mumajeqwcu1g.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:10:46", "published_display": "25 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Prices Equity Offering for ~$187.4 Million Net, Grants 5 Million Share Option", "summary": "Taysha Gene Therapies announced an equity offering to sell over 33 million shares and pre-funded warrants at $6.00 per share, expecting to net approximately $187.4 million. The company has also granted underwriters an option to purchase up to 5 million additional shares, which co", "url": "https://www.tradingview.com/news/tradingview:5678614f78299:0-taysha-gene-therapies-prices-equity-offering-for-187-4-million-net-grants-5-million-share-option/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:46", "published_display": "25 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (NASDAQ: TSHA) prices $200M equity raise with warrants", "summary": "Taysha Gene Therapies (NASDAQ: TSHA) has priced an underwritten public offering to raise approximately $200 million in gross proceeds through the sale of common stock and pre-funded warrants. The company will sell 32,500,001 common shares at $6.00 each and pre-funded warrants for", "url": "https://www.stocktitan.net/sec-filings/TSHA/8-k-taysha-gene-therapies-inc-reports-material-event-4ee76b43942b.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:10:46", "published_display": "25 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Down Over 11%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk", "summary": "Taysha Gene Therapies (TSHA) stock is down over 11% today, experiencing its largest percentage decrease since May 2025. This downturn follows five consecutive days of gains, during which the stock rose by 4.2%. The current trading volume is significantly lower than its 65-day ave", "url": "https://www.moomoo.com/news/post/72053872/taysha-gene-therapies-down-over-11-on-pace-for-largest?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-25T19:10:46", "published_display": "25 Jun 2026 19:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Prices $200 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/taysha-gene-therapies-prices-200-084319338.html", "source_name": "MT Newswires", "published_at": "2026-06-25T08:43:19+00:00", "published_display": "25 Jun 2026 08:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Prices $200 Million Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNaU5fbjBSREU5UnZ1VFFjX1ZnZUhfX0d5VkJZcUZuRFo5eXpYNExmTEtkXzB4ZEowTlU1WGNRVE1oSUVOeUNWRHV5bjkwSWpYdFBBZ29MaTN1ei1nXzdvbjgzczMtTnM5aGFqYUVRVnE5czhkZlp6VXRNQVh6a1BEWkVtRU9hdEFXLWN2X1dkNUVXVV9heGNuUXhwYU9Pb3M2ei1saFpudVhSQkdvWlRBeGVJLXdqbU0xeDJrSWZSZFJabXhPUVdNenVCXzM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies stock tumbles on public offering pricing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNS1FEXzZQeVBleVJjQzF4MTVSNGJwVDlRdmlXbGxaLWdWSFhRLW51YU1MenI1Z1pLM19iSk9tLUJqN1VmTi1RTGVnVXd6YXVQSVpDYmFhYzNZWU42Y01QSjlISFFlcVdTVTRTdFFWakhsZDV2RDMya0w1WERKMlhHeWRLc1RXMVZnQUg5djI1d1VPZ1FZbDA3Nmt0OTZtaVc0Z1J1bjRUa2l2WFJsRGJmSlRTbTR1SXVtSzJOOGxhemhEQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Inc Files For Mixed Shelf Offering Of Up To $200 Million - SEC Filing", "summary": "Taysha Gene Therapies Inc has filed for a mixed shelf offering of up to $200 million, as disclosed in an SEC filing. This information was reported as part of standard financial news.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42W0GB:0-taysha-gene-therapies-inc-files-for-mixed-shelf-offering-of-up-to-200-million-sec-filing/", "source_name": "TradingView", "published_at": "2026-06-25T03:41:06", "published_display": "25 Jun 2026 03:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies prices $200M stock offering at $6 per share", "summary": "Taysha Gene Therapies has priced an underwritten public offering of 32,500,001 shares of common stock at $6.00 per share, aiming to raise approximately $200 million. The company also offered pre-funded warrants and granted underwriters a 30-day option for additional shares. This ", "url": "https://www.investing.com/news/company-news/taysha-gene-therapies-prices-200m-stock-offering-at-6-per-share-93CH-4759639", "source_name": "Investing.com", "published_at": "2026-06-25T03:03:06", "published_display": "25 Jun 2026 03:03", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Launches $200 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/taysha-gene-therapies-launches-200-202528925.html", "source_name": "MT Newswires", "published_at": "2026-06-24T20:25:28+00:00", "published_display": "24 Jun 2026 20:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxQZXlnMjRETmtoMjNEZVJ2T1hpR0JVYmxFcmpvWnllMjZDSDRKRGNFNTNKNjlDUGlMVDEzTkN3SGhzenRFdG1zMzh0Q3pjd3NwUW5IOE9GZGZaOF83cURtQlo3bzVoRHJwUTgxdUZTY3VMbUFDY09vWXlOek5UYkUtX2pwTHQ2WU5OVVB3X3hjYWZ3eEE1R19jU3EzOTJTQUdlVm41TE9pVndWQ2UzN2dndDNrRm80U1F4X1l2RUJDMGZ6c18tRy11UGVWSDI1ZzRvNGRNQ3pRMmx5UnFocnFNY2tTdlpvWmNVSXQ2RkJWNmptblRaWHlrbkJIa3B2a2c?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxPbldxZDlTZFdQQUFGdXJUaU9YWmlYbmpBeGdyemtmV2tERVJjTkxteEx0bUF0OE1RN2tSM0pFZldvbTJtWWlEZTZfYkFyb2h1Y19na3N6Rnhvc2lNZk9RY3pJLUpheVVUSHd1QmMyWkFhbzhBVUpWcE1hSTlsbmlGS3hxOXgwMTdWNWcwLVlScDBzVW5OYWMwMFlPQ3VJOEtCWkRRM3RveUtXU0U0QXFZR1NSRkw2RlcxWHJYbXhQbFJOQVJJU1lvZ0JWWnNtUHpoUklQbjdTekJTMUhUOWRaVHFYcFRUUlE0VUNmV2Z5ZmtFMDZIOFV2MDBZNkY?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (TSHA) files $200M common stock and pre-funded warrants offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQN0pCRlRZcWtnSGJTOGs5SFBkRDBPandoMU1SNjVJWndwbUVyOG5OMGtWRlhUdllOSEptM0lFd29iZWxuZTlJNmNTSE93cDBTSjFPbmlzM2daQ0NNeFYxOU84VEtvY29zVGo3TWZvVG1GYVc4WEJIVWtYSXBIVUduQUdmOFl5Tm5NaDJGcHBuTjNraUVGWlZwazZBMUNsYjh3Qml4TjVZc29MUVNYYzlwaDRsYVQwZGlSRGF6dTZVQkZxVWJpWVFMcVVDdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha prices $200M offering as closing nears June 26", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRUxGeFVpcFY2aEV0UmkzX01IaFNIYkRRSGRCaXlCUGJfVUgxbjd2bHQ2b3Y2andQYUNhcUJHWXZ4VVh2X2Y3SEZIUE1tUi1FTFNZdW92aG85elkzVlp4MHQ2UzhtT3BnQUZ2a1ZxSmZnVFlOTE50eURmYWtrQ1FaWG5xc05mZzQ5d0E3S2hFQU9vV0llVjBLYk1BX3F5Vm9VN2paSWdndUx3blpfRVJ5Tl9uaThwWUlBQVRaS3ZjZG8?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)", "summary": "", "url": "https://finance.yahoo.com/m/3db0036d-6fb1-3e40-ab7a-37807122dabc/taysha-advances-rett-syndrome.html", "source_name": "InvestorsHub", "published_at": "2026-06-22T12:56:24+00:00", "published_display": "22 Jun 2026 12:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies stock price target raised to $10 by BofA on trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQWnBpdzF4RkZDa3kwNXMzZE1QUXdxNVFvSDdkaFY1SDhma0pZN2RubEtZUFhwSm1KcFNCR2NtaE03OVdCazJFTTQ1dWhnUXh0Q2pZMEJDVFJNbUNrOWt1V1NxamJnZHNtcXJBWVd2SW9KUE82YVJnM2ZObnVlZDZoTWtkb2U1SW9QQ1lHeGVEOEJ2WElad1Bpb0NLdHhZcEtqQjRLZFVpczVfQ0swQkJWeDJMT3FCRnJzT0xBNUJlbUZVeG9Yd1h4TjRmM3lMT2JQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year Recovery", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNLTRmeFRWaDB1ckdoZFQ0bVh4SlMzMUFKX1BvMWFmOG0zWFI2T1lXazZaWGY3LWlMVy1KeDlpRXVrMXJQZHdMSWRBb1lsVGJoMEtaMjdMM3dhZkdEeklkenJoVG9LNnRncVhBY3FELTJNZ2k2RWQ2TERnTWhObzBWTGhhbmFvek1zd0hwN3ZnVTVac0tVQWNoRWt5MVYwQ0IwenJB?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQQnBDVHBPMm1CYmNsVGF6WFluSlkzTzJTdkVlZWMyZVJ5REVvYnlRbEl2VkNINVRoWDdDMGpCejV2VzVUMlJvcnlkaGRyZW9QODdSd2JvQTA4R3AwSllETHpKUWxPclBzWFJoa2NZbFZ3SVI2V2lmMU1kWWZXOTJfNjlaTk5pZ1M5dkVWUGU2NWFMbFBydUw2OVdOWQ?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies: Shortened Timeline Increases The Potential (NASDAQ:TSHA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOUVV3anZ6WnBtQU1rSHo5QWJLaUdCM2JpR1NKSDVyVFR1NXNVSG9GU1FGTDNqMk5yU0Z5NHpFUUpDTE9xWjBrRmZ1cDFsVmR1U0hsNDdKcEo1MGx0cFM0eWpZcGlwZmY1MHdaRzREZ1ZHcnRSbGozdGhkUm5FdUxLa1VfcVRfMi0xUXhJNm9jeEJhaXppdVQ2MWN4bDVYM0JscFRNVTZveHpJZ0RITFQ3MQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQcGJEclQ2QW5tOC1OM2lvZHo5NlNKSjV2X0NIRS1qRjBzZG41RGJyNTFNUWRDSmp4RHFyMFRxTm5XNEZPbk1iazYxQW9LM1lkd2ZCZkpBMjV2TjdSWXBuTTh3eTVpa2JHV3FFblVuTEdVVmFmeTdHQmlkT2hfRTI4WkNHbGdhZVQwZkVrdU9oZkFYbWxScDR5YmtLRTBjUmdzMk41LWpn?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOSjBBWGdEUEU1Y3hyR3dKSGpwSG02OGphODFUVS1YR24zQ3I3UmJHeTZValZsNXJoRlp0SW82bHZFaDdYY21ZaWRBd0JiZE9jRmc0UUt5SHVhOVlySW1XOHlOcnljN0tXVUNsWTh1T1RidzJlSGhlUDJpcWNzenNadzBtRlI4b1RCZnVZWGVEeFQyY0JBcjROUmYwMGlEU00xUFc0?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A 6-month trial readout could shape Taysha's gene therapy filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOUjg5S0htMGFFTDJEck1ETFMwOHZ0VVp4RHp1bm9oeHhDVWwtdTZnOHRvQ2VHTmgzdFZPMzN4TVM2Q0txYXhydkVNRkVhQS1ZNzFFdm41NGI0SzlzVXRTZW9KSFZ1c0JYeEN4clk1eEtsa1h6alA5NmNpVEJSZ0dOVGxlb1dXUERNeklueHBCa25lUlhtV05MZHNRU3Btb3FyYkRtUFBWMU5GeGZHbl8xcWJQTU1YQmI2b1ZmbERn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxObUpDY2NpUkdxcjlPeFJtTHFoaXRuZ0hDdXRtbl80d21CRWZrdjkwZGxBUWpnWTI5dndBa2pVR1B2b3N3UUtyampUa2piRW4zZ1F2S3lKaUREUUFXZlVJeUswRHIzcUdEM1FuMXZDOVVmTy05UkFMTzFtd296ZGx6dkRCbkE1Z2VwN1dKby1YVnBhYXRBNnBQMFZ2X1htaFBXTC01bFdzbWxvZDdOaUp3VmNTMFdET3NaQnlQT0VidlhTcnpzbkU1UFRVWERkUEdTVlJLVEhoVm1GbU92MnNKQnVNcHFvS1ZVaV9sVDY2c3F1a2Z2YUJZcVZKT3g?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxONEdFV3UzY2wyaFhHVHB4TWxlZDZjbXM2VkkwWkVyckZzYUJQRzAtOUNINjZtUGcwQUJ6cTVzZnRicEwwZllsSU1uWTRfaUNtRWFPRGFhUDBHOVJrTG1Dc2VmUFAxU1lVWWR5c1BqR19vNFFMdlJZMWlzS1FZZnprc09RWjdsczRVc3ZaS0NJeHg4NXBGdU9jOWdYZw?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies Reports Preclinical Data Supporting TSHA-102 Gene Therapy for Rett Syndrome at ASGCT Annual Meeting | TSHA Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNRU13QXU5RFkyTHhfdkZMUGJoaVpYam9BMkZpYkZONHNXNnZFbmdKbGNJRk1jR0R0MUFTVjZXQnZiNXhONU44S1M0bU00c1hiVmVlZUZYd3pwT09GbjNTTEd4RUxfRFY1S1ZzY0E4LWpDRlBVUjlVaEdrZ3p3bWFDM2xkTWtEVlNHY0NKNFMwX3BkZ21sb19rNHdVcmtQYzVLSlhmbEFPNEpJZTVzcVM0dXl2WmNIWFEwM19iNkpRMVk2Z19IajN5dE5EX19GUkc0djgxRlVjdGFwWEEyWGhPQmxpVXJTQ05mMVE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQaG9nZGZUbjlZUnJyLWVOVTZWRi1WbTJQUFYzSlJWdEpfRmpLclNYZndKbFRtQzJ2YW9rMTBlcG95NFRGMkNqa0pQSjBOWEUxbE5HdlFoYWMyZ203Rm9Uc1BVMHFrRjdsYWlORjE5RWZMWlN3Z1Z4Z3lmQ3BuMGh2NGhjTmpOMjFuQ3FvSHQ0cEJ5WnNoSGpwSXFsNjI2Yi1zd2JJ?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 65, "sentiment_summary": {"positive": 17, "negative": 9, "neutral": 39, "score": 52, "total": 65, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 88, "events": [{"event": "general", "label": "Market update", "weight": 27.85, "count": 50}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 17, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 5.96, "latest_week": "2026-07-17", "one_week_move": -6.0, "four_week_move": -7.2, "twelve_week_move": -6.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.464631, "market_dynamics_buy_signal": false, "relative_strength": 14.092622, "fair_value_gap": 95.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 50.7796, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.0% over one week, -7.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 8}, {"label": "Investing.com", "count": 6}, {"label": "GlobeNewswire", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "Simply Wall Street", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 57}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 50}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "88/100 classification confidence."}, {"label": "Company focus", "value": "57", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-6.0% over one week, -7.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Does Rett Trial Data and Share Offering Reshape the Bull Case for Taysha Gene Therapies (TSHA)?"}], "updated_at": "2026-07-19T17:51:50.920438+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}